Becton, Dickinson and Company $BDX Position Raised by Bristol John W & Co. Inc. NY

Bristol John W & Co. Inc. NY boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 40.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 589,386 shares of the medical instruments supplier’s stock after purchasing an additional 170,411 shares during the period. Becton, Dickinson and Company makes up about 1.7% of Bristol John W & Co. Inc. NY’s portfolio, making the stock its 23rd largest holding. Bristol John W & Co. Inc. NY owned 0.21% of Becton, Dickinson and Company worth $110,315,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Becton, Dickinson and Company by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock worth $6,074,750,000 after buying an additional 147,041 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in Becton, Dickinson and Company by 13.8% during the third quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock valued at $1,870,653,000 after buying an additional 1,208,218 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Becton, Dickinson and Company by 7.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 9,150,584 shares of the medical instruments supplier’s stock worth $1,712,715,000 after acquiring an additional 636,138 shares during the period. Geode Capital Management LLC grew its holdings in Becton, Dickinson and Company by 3.8% during the second quarter. Geode Capital Management LLC now owns 6,723,702 shares of the medical instruments supplier’s stock worth $1,153,157,000 after acquiring an additional 244,199 shares during the period. Finally, Norges Bank bought a new stake in Becton, Dickinson and Company in the second quarter worth about $653,377,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $159.37 on Friday. The company has a 50-day moving average of $190.72 and a two-hundred day moving average of $190.28. The stock has a market cap of $45.38 billion, a price-to-earnings ratio of 26.00, a PEG ratio of 11.83 and a beta of 0.24. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. During the same quarter in the previous year, the business earned $3.43 earnings per share. The firm’s revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is 68.52%.

Becton, Dickinson and Company announced that its board has initiated a share repurchase program on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

BDX has been the subject of several research reports. Royal Bank Of Canada set a $172.00 price objective on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Wells Fargo & Company dropped their target price on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 10th. Piper Sandler restated a “neutral” rating and set a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. JPMorgan Chase & Co. decreased their price target on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Finally, Citigroup dropped their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $195.46.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,416 shares of company stock valued at $674,693 in the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.